Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study

BACKGROUND: We conducted an exploratory study to assess the safety tolerability, and anti-fibrotic effects of PRI-724, a CBP/β-catenin inhibitor, in patients with hepatitis C virus (HCV)- and hepatitis B virus (HBV)-induced cirrhosis. METHODS: This multicentre, open-label, non-randomised, non-placeb...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Kiminori, Kanto, Tatsuya, Shimoda, Shinji, Harada, Kenichi, Kimura, Masamichi, Nishikawa, Koji, Imamura, Jun, Ogawa, Eiichi, Saio, Masanao, Ikura, Yoshihiro, Okusaka, Takuji, Inoue, Kazuaki, Ishikawa, Tetsuya, Ieiri, Ichiro, Kishimoto, Junji, Todaka, Koji, Kamisawa, Terumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126795/
https://www.ncbi.nlm.nih.gov/pubmed/35605429
http://dx.doi.org/10.1016/j.ebiom.2022.104069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126795/
https://www.ncbi.nlm.nih.gov/pubmed/35605429
http://dx.doi.org/10.1016/j.ebiom.2022.104069

Ejemplares similares